Development and validation of a gene expression-based Breast Cancer Purity Score

Area of Science:

• Oncology
• Genomics
• Bioinformatics

Background:

• Tumor purity, the proportion of malignant cells, influences molecular profiling of bulk samples.
• Variability in tumor purity introduces bias in data analysis and interpretation.
• Existing methods for estimating tumor purity lack breast cancer specificity.

Purpose of the Study:

• To develop and validate a novel, breast cancer-specific method for estimating tumor purity.
• To assess the performance of the new method against existing techniques.
• To evaluate the utility of the new score in improving molecular data interpretation and clinical prognostication.

Main Methods:

• Interrogation of over 6000 expression profiles from 10 diverse breast cancer datasets.
• Development and validation of a 9-gene Breast Cancer Purity Score (BCPS).
• Comparative analysis of BCPS against existing tumor purity estimation methods.

Main Results:

• The developed BCPS demonstrated superior performance in estimating tumor content compared to existing methods.
• Adjusting transcriptomic profiles with BCPS effectively reduced sampling bias and aided data interpretation.
• BCPS-estimated tumor purity showed improved prognostication in luminal breast cancer.
• BCPS correlated with pathologic complete response in triple-negative breast cancer patients.
• BCPS stratified relapse risk in HER2+ residual disease post-neoadjuvant treatment.

Conclusions:

• The 9-gene BCPS is a robust and accurate tool for estimating tumor purity in breast cancer.
• BCPS facilitates more reliable molecular data analysis and interpretation in large clinical cohorts.
• Application of BCPS enhances clinical prognostication and prediction of treatment outcomes in various breast cancer subtypes.